Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing on ...

Mounjaro has sold more than 81,570 units in India, totalling about ₹23.94 crore ($2.76 million) as of May, with the drug ...

GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

Investing.com -- The American College of Cardiology released new recommendations on Friday stating that millions more ...

GLP-1 drugs such as Wegovy and Zepbound are growing increasingly prominent. But some food ingredients can also cause the body ...

Millions more Americans should be taking weight-loss drugs to prevent heart disease, according to the American College of ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Shares of weight-loss drugmakers Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) spiked after the American College of Cardiology ...

Novo is expected to launch Wegovy in India, early next week. The tablet version of semaglutide, used in treating Type-II ...

GLP-1 medications such as Wegovy, Mounjaro and Ozempic helped drive a 9% year-over-year increase in U.S. prescription dispensing revenue, which reached $683 billion in 2024.  A separate report found ...

It has been reported that Novo Nordisk may have inadvertently allowed generics of its GLP-1 agonist semaglutide, the active ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.